Document Classification

Section Type: RESULTS

Text: For subjects randomized to atorvastatin versus placebo, a primary end point occurred in 13. 1 % versus 18. 6 % of those classified as having large vessel disease (LVD, 15. 8 % of 4, 731 participants), in 13. 1 % versus 15. 5 % of those with small vessel disease (SVD, 29. 8 %), in 11. 2 % versus 12. 7 % of those with ischemic stroke of unknown cause (21. 5 %), in 7. 6 % versus 8. 8 % of those with TIA (30. 9 %), and in 22. 2 % versus 8. 3 % of those with hemorrhagic stroke (HS, 2 %) at baseline.